Cargando…
Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparin...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288045/ https://www.ncbi.nlm.nih.gov/pubmed/34290991 http://dx.doi.org/10.3389/fonc.2021.716002 |
_version_ | 1783724023410065408 |
---|---|
author | Baron, Jonathan Wright, Christopher M. Lee, Daniel Y. Carpenter, Maribel Manjunath, Shwetha H. Briceño, César A. Chong, Elise Maity, Amit Plastaras, John P. Paydar, Ima |
author_facet | Baron, Jonathan Wright, Christopher M. Lee, Daniel Y. Carpenter, Maribel Manjunath, Shwetha H. Briceño, César A. Chong, Elise Maity, Amit Plastaras, John P. Paydar, Ima |
author_sort | Baron, Jonathan |
collection | PubMed |
description | PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 – 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT. METHODS: A total of 36 patients treated with 38 consecutive courses of RT were identified; LDRT was delivered for 14 courses and MDRT for 24 courses. Overall response rates (ORR) were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or partial response. Local control (LC), orbital control (OC), and overall survival (OS) rates were estimated with the Kaplan-Meier method. RT toxicity was graded per CTCAEv5 and compared with the Fisher’s exact test. RESULTS: Median follow-up time was 29 months (m) (range, 4-129m), and median MDRT dose used was 24 Gy (range 21-36 Gy). Overall response rates (ORR) were 100% (CR 50%) and 87.5% (CR 58.3%) following LDRT and MDRT, respectively. OS at 2 years was 100% and 95% for the LDRT and MDRT groups, respectively (p=0.36). LC rates at 2 years was 100% for both LDRT and MDRT groups and at 4 years was 100% and 89% for the LDRT and MDRT groups, respectively (p=0.56). The 4-year OC rate (including both ipsilateral and contralateral relapses) was 80% and 85% for the LDRT and MDRT groups, respectively (p=0.79). No patient required treatment with RT to a previously irradiated orbit. Acute toxicities were reported following 6 LDRT courses compared to 20 MDRT courses (p=.014). No Grade 3 or higher acute toxicities occurred in either group. Late toxicities were reported following 2 LDRT courses compared to 10 MDRT courses (p=0.147). CONCLUSIONS: LDRT produced similar ORR, LC, OC, and OS rates compared to MDRT with fewer acute and minimal late toxicities reported. Future multi-center studies with larger patient numbers are warranted to show significant associations. |
format | Online Article Text |
id | pubmed-8288045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82880452021-07-20 Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas Baron, Jonathan Wright, Christopher M. Lee, Daniel Y. Carpenter, Maribel Manjunath, Shwetha H. Briceño, César A. Chong, Elise Maity, Amit Plastaras, John P. Paydar, Ima Front Oncol Oncology PURPOSE: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 – 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT. METHODS: A total of 36 patients treated with 38 consecutive courses of RT were identified; LDRT was delivered for 14 courses and MDRT for 24 courses. Overall response rates (ORR) were recorded according to Deauville or RECIST criteria with a response characterized as a complete response (CR) or partial response. Local control (LC), orbital control (OC), and overall survival (OS) rates were estimated with the Kaplan-Meier method. RT toxicity was graded per CTCAEv5 and compared with the Fisher’s exact test. RESULTS: Median follow-up time was 29 months (m) (range, 4-129m), and median MDRT dose used was 24 Gy (range 21-36 Gy). Overall response rates (ORR) were 100% (CR 50%) and 87.5% (CR 58.3%) following LDRT and MDRT, respectively. OS at 2 years was 100% and 95% for the LDRT and MDRT groups, respectively (p=0.36). LC rates at 2 years was 100% for both LDRT and MDRT groups and at 4 years was 100% and 89% for the LDRT and MDRT groups, respectively (p=0.56). The 4-year OC rate (including both ipsilateral and contralateral relapses) was 80% and 85% for the LDRT and MDRT groups, respectively (p=0.79). No patient required treatment with RT to a previously irradiated orbit. Acute toxicities were reported following 6 LDRT courses compared to 20 MDRT courses (p=.014). No Grade 3 or higher acute toxicities occurred in either group. Late toxicities were reported following 2 LDRT courses compared to 10 MDRT courses (p=0.147). CONCLUSIONS: LDRT produced similar ORR, LC, OC, and OS rates compared to MDRT with fewer acute and minimal late toxicities reported. Future multi-center studies with larger patient numbers are warranted to show significant associations. Frontiers Media S.A. 2021-07-05 /pmc/articles/PMC8288045/ /pubmed/34290991 http://dx.doi.org/10.3389/fonc.2021.716002 Text en Copyright © 2021 Baron, Wright, Lee, Carpenter, Manjunath, Briceño, Chong, Maity, Plastaras and Paydar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Baron, Jonathan Wright, Christopher M. Lee, Daniel Y. Carpenter, Maribel Manjunath, Shwetha H. Briceño, César A. Chong, Elise Maity, Amit Plastaras, John P. Paydar, Ima Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title | Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title_full | Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title_fullStr | Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title_full_unstemmed | Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title_short | Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas |
title_sort | low-dose radiotherapy versus moderate-dose radiotherapy for the treatment of indolent orbital adnexal lymphomas |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288045/ https://www.ncbi.nlm.nih.gov/pubmed/34290991 http://dx.doi.org/10.3389/fonc.2021.716002 |
work_keys_str_mv | AT baronjonathan lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT wrightchristopherm lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT leedaniely lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT carpentermaribel lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT manjunathshwethah lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT bricenocesara lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT chongelise lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT maityamit lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT plastarasjohnp lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas AT paydarima lowdoseradiotherapyversusmoderatedoseradiotherapyforthetreatmentofindolentorbitaladnexallymphomas |